Cytek Biosciences, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Cytek reported Q3 2026 revenue of $53.2M (2% YoY increase) with GAAP gross margin improving 590 basis points to 59%. Recurring revenue (service + reagent) reached $19.1M (36% of total, up from 33% YoY). Installed base expanded to 4,073 instruments (+140 units). Company maintained full-year 2026 revenue guidance midpoint and narrowed range to $208–$211M. Net loss was $6.1M vs. $5.5M YoY; adjusted EBITDA declined to $0.7M from $2.5M.
Why this rating
Modest 2% revenue growth and narrowed (not raised) guidance mixed with strong margin expansion. Adjusted EBITDA decline and rising G&A costs offset positives. Material relative to $393M market cap but not trajectory-changing.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.